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Abstract
Several LIM domain proteins regulate transcription. They are thought to act through their LIM protein-protein interaction
domains as adaptors for the recruitment of transcriptional co-regulators. An intriguing example is nTRIP6, the nuclear
isoform of the focal adhesion protein TRIP6. nTRIP6 interacts with AP-1 and enhances its transcriptional activity. nTRIP6 is
also essential for the transrepression of AP-1 by the glucocorticoid receptor (GR), by mediating GR tethering to promoter-
bound AP-1. Here we report on the molecular mechanism by which nTRIP6 exerts these effects. Both the LIM domains and
the pre-LIM region of nTRIP6 are necessary for its co-activator function for AP-1. Discrete domains within the pre-LIM region
mediate the dimerization of nTRIP6 at the promoter, which enables the recruitment of the Mediator complex subunits
THRAP3 and Med1. This recruitment is blocked by GR, through a competition between GR and THRAP3 for the interaction
with the LIM domains of nTRIP6. Thus, nTRIP6 both positively and negatively regulates transcription by orchestrating the
recruitment of the Mediator complex to AP-1-regulated promoters.
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Introduction
After binding to their cognate DNA response elements in the
regulatory regions of their target genes, sequence-specific tran-
scription factors activate transcription through the recruitment of
transcriptional co-activators. Co-activators are defined as factors
which do not directly bind DNA but are recruited to promoters
through a direct or indirect interaction with DNA-binding
transcription factors, and which participate in the activation of
transcription. Co-activators are generally classified according to
the mechanism by which they promote transcriptional activation
(reviewed in [1,2]). This can be for example the modification of
histone tails, the remodelling of nucleosomes, or the recruitment
and stimulation of the basal transcription machinery. These
different functions are dynamically coordinated through the
sequential recruitment and release of specific co-activators or
multi-protein co-activator complexes at the promoter [reviewed in
3,4]. A prominent role in this orchestration is that played by
adaptor proteins. These proteins formally match the definition of
co-activators, in that they are recruited to promoters via an
interaction with transcription factors and are involved in
transcriptional activation. However their role is to recruit other
factors which function as co-activators. One of the early examples
of such an adaptor protein is CBP/p300. Although this large
protein acts as a co-activator through its intrinsic histone acetyl-
transferase activity [5,6], it also serves as an adaptor protein, by
interacting with other essential co-activators such as SRC-1 or p/
CAF (reviewed in [7,8]), thus enabling the recruitment of larger
co-activator complexes. Other co-activators act only as adaptor
proteins. This is the case for a group of LIM domain-containing
co-activators (reviewed in [9,10]). The LIM domain, first identified
in the Lin-11, Isl-1 and Mec-3 homeodomain transcription factors,
is defined as a cysteine-rich motif organized as a double zinc finger
structure, which mediates protein-protein interactions. Some LIM
domain proteins consist of nearly exclusively LIM domains (LIM-
only proteins), and yet act as co-activators. For example, the Four-
and-a-Half LIM domain protein 2 (FHL2) acts as a co-activator
for the androgen receptor [11] and for CREB [12], whereas the
LIM-only protein 4 (LMO4), which consists of only 2 LIM
domains, co-activates Peroxisome Proliferator-Activated Recep-
tor-c [13] and Smad4 [14]. Given that the only functional
domains in these LIM proteins are protein-protein interaction
modules, the only way they can act on transcription is as adaptors
recruiting other co-activators.
A particularly intriguing class of LIM domain proteins are
members of the Zyxin and Paxillin families of so-called focal
adhesion LIM domain proteins. The proteins of this group
are cytosolic, enriched at sites of focal adhesion, and are known
to regulate adhesion and migration (reviewed in [10]).
Surprisingly, LIM domain proteins of this class also exert co-
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activator or co-repressor functions for various transcription factors,
and have thus been proposed to shuttle from the cytoplasm to the
nucleus to regulate transcription (reviewed in [15,16]). Amongst
these proteins a particular case is that of TRIP6 (reviewed in
[17,18]). We have reported that this protein is not shuttling, but
that its nuclear functions are mediated by a shorter, exclusively
nuclear isoform, which we termed nTRIP6 [19]. nTRIP6 acts as a
co-activator for the transcription factors AP-1, NF-kB and the
glucocorticoid receptor (GR). nTRIP6 interacts with these
transcription factors, is recruited to the transcription factor-bound
target promoters via this interaction, and is required for the
activation of transcription [19–21]. Thus, nTRIP6 fulfils the
definition of a co-activator. Like the other members of the Zyxin
family of LIM domain proteins, nTRIP6 harbours three C-
terminal LIM domains [22] with interaction specificities for the
transcription factors mentioned above [19]. The N-terminal pre-
LIM region does not contain any known functional domains which
could account for the co-activator function. Therefore, we favour
the hypothesis that nTRIP6 acts as an adaptor protein, which
promotes the recruitment of other co-activators or co-activator
complexes to transcription factor-bound promoters.
Another essential function of nTRIP6 is to mediate the
repressive crosstalk between AP-1 and GR, a phenomenon
referred to as transrepression [23–28]. In this mode of action,
GR does not act as a transcription factor but rather as a co-
repressor for AP-1, in that it is tethered to the AP-1-bound
promoter through protein-protein interactions, leading to tran-
scriptional repression [19,29–32]. We have previously reported
that through the selectivity of its LIM domains, nTRIP6 mediates
the tethering of GR to the promoter of AP-1 target genes [19,20].
However, the mechanism by which this nTRIP6-dependent
tethering leads to repression has remained unclear.
We report here that unexpectedly, both the pre-LIM region and
the LIM domains of nTRIP6 are required for its co-activator
function. nTRIP6 homodimerizes through discrete domains
within its pre-LIM region, and this homodimerization is required
for the co-activator function of nTRIP6 for AP-1. Mechanistically,
our data demonstrate that nTRIP6 homodimerization enables the
recruitment of the Mediator complex subunit THRAP3 to the
promoters, through the interaction of THRAP3 with the LIM
domains. Furthermore, we show that GR prevents the interaction
between nTRIP6 and THRAP3, inhibits THRAP3 recruitment to
AP-1 target promoters, and thereby represses AP-1 activity. These




The luciferase reporter constructs were as previously described:
MMP1-Luc [33], GAL-Luc [34] and Ubi-Renilla [19].
pcDNA3.1HA-nTRIP6 has been described [19]. pcDNA3.1HA-
preLIM and pcDNA3.1HA-LIM were constructed by PCR
amplification of the sequence encoding the nTRIP6 pre-LIM
region, lacking the LIM domains, and of the LIM domains of
TRIP6, respectively, and subcloning into pcDNA3.1HA [19]. The
GAL4 DNA binding domains fusions of nTRIP6, preLIM and
LIM were generated by PCR and subcloning into pcDNAGalDBD
[19]. The constructs for bimolecular fluorescence complementa-
tion assays (BiFC; [35,36]) were cloned as follows: the C- and N-
terminal halves of the Venus fluorescent protein (provided by
Chang-Deng Hu, Purdue University, West Lafayette IN) were
PCR-amplified and cloned between the NotI and XbaI
sites of pcDNA3.1HA to obtain pcDNA3.1HA-VC and
pcDNA3.1HA-VN, respectively. pcDNA3.1HA-nTRIP6-VC,
pcDNA3.1HA-nTRIP6-VN, pcDNA3.1HA-preLIM-VC and
pcDNA3.1HA-LIM-VC were obtained by cloning the corre-
sponding PCR fragments into pcDNA3.1HA-VC or
pcDNA3.1HA-VN. The BiFC deletion constructs lacking either
the dimerization domain 1 (DD1) or the dimerization domain 2
(DD2) were generated using the In-Fusion HD cloning kit
(Clontech, Saint-Germain-en-Laye, France) according to the
manufacturer’s instructions, and cloned into pcDNA3.1HA-VC
and pcDNA3.1HA-VN. The fusions to the C-terminal half of YFP
(YC) of nTRIP6 and its LIM mutants, in which the coordinating
cysteines of the two zinc fingers of either the first or the third LIM
domains were mutated to alanines (LIM1 and LIM3m), have been
described [21]. Similarly, in pcDNA3.1-nTRIP6-LIM2m-YC, the
first two coordinating cysteines in both zinc fingers of the second
LIM domain were mutated to alanine using the QuickChange
Site-Directed mutagenesis kit (Stratagene, Heidelberg, Germany).
pcDNA-mCherry-NES and pGEX-4T-3-nTRIP6 for GST-
nTRIP6 expression have been described [21]. The pCG
expression vectors for the single-chain AP-1 constructs c-
Jun,ATF2 and c-Jun,c-Fos [37] were from Latifa Bakiri
(Spanish National Cancer Center, Madrid, Spain). The
mCherry-tagged, nuclear targeted blocking peptides DD1 and
DD2, as well as their scrambled control versions DD1c and DD2c,
were obtained by cloning mCherry (provided by Roger Y. Tsien,
University of California, San Diego, La Jolla CA) between the
NheI and KpnI sites, an oligonucleotide encoding the nuclear
localization signal of the SV40 virus between the KpnI and
BamHI sites, and oligonucleotides encoding the peptides between
the BamHI and XbaI sites of pcDNA3.1. The THRAP3
(TRAP150) expression vector pcDNA-TRAP150-FLAG [38]
was a gift from Woan-yuh Tarn (National Taiwan University,
Taipei, Taiwan). For BiFC experiments, THRAP3 was fused with
the N-terminal half of YFP (YN), using the In-Fusion cloning kit,
and cloned into pcDNA3.1. pDBN-AR1 [39] for the generation of
the MMP1-Luc array cell line was obtained from Noriaki Shimizu
(Hiroshima University, Hiroshima, Japan). pcDNA3.1-GR has
been described [19].
Cell culture and transfections
HeLa, HEK-293, Cos7 and NIH-3T3 fibroblasts (ATCC, LGC
Standards GmbH, Wesel; Germany) were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal
calf serum. For reporter gene assays and BiFC experiments, cells
were transfected using PromoFectin (PromoKine, Heidelberg,
Germany). For mRNA analysis cells were transfected using
Screenfect (Incella, Graben-Neudorf, Germany).
Synthetic siRNA duplexes were purchased from Eurofins MWG
Operon (Ebersberg Germany). HEK-293 cells were transfected
with a mixture of two siRNAs targeting THRAP3 mRNA
(sequence as in [40]), or a control siRNA targeting dsRed [41]
using Lipofectamine 2000 (Invitrogen GmbH, Karlsruhe, Ger-
many).
Stable NIH-3T3 clones bearing an array of amplified MMP1-
Luc gene unit were obtained by blasticidin selection after
cotransfection of equimolar amounts of MMP1-Luc and pDBN-
AR1, which promotes an amplification of cotransfected plasmids
[39]. Copy number was estimated as previously described
[20,21,42] by real-time PCR analysis, using primers amplifying
both the Chinese hamster DHFR genomic region contained in
pDBN-AR1 and the endogenous mouse counterpart. The
presence of the array was confirmed by fluorescence in situ
hybridization (FISH), as described ([20,21]; see Material and
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Methods S1). The stable array cells were further transfected using
JetPEI (PEQLAB Biotechnologie, Erlangen Germany).
All experiments were performed in serum-starved (24 h) cells.
Unless otherwise stated, cells were treated 24 h post-transfection
with solvent alone or 50 ng/ml TPA (Sigma-Aldrich, Munich,
Germany), in the presence or absence of 1 mM dexamethasone
(Sigma-Aldrich). In siRNA experiments, cells were treated 48 h
post-transfection. For reporter gene assays, cells were harvested
16 h post-treatment. Except for the experiments with Cos7 cells
overexpressing THRAP3, firefly luciferase activities were normal-
ized to Renilla luciferase activities (Ubi-Renilla). Cells were
harvested 4 h after TPA treatment for mRNA analysis, or 3 h
after TPA treatment for chromatin immunoprecipitation and
array cells imaging.
Western blotting
Western blot analyses were performed using the following
antibodies: anti-THRAP3 (Novus Biologicals, Littleton, CO); anti-
c-Fos (Upstate, Schwalbach, Germany); anti-HA (clone 3F10,
Roche Applied Science, Mannheim, Germany); anti-GR (clone
4H2; Novocastra); anti-actin (Santa Cruz, Heidelberg, Germany).
BiFC, Immunofluorescence, and Laser Scanning
Microscopy
For Bimolecular fluorescence complementation assays (BiFC;
[35,36]), cells were grown and transfected in eight-well chamber
slides (NUNC, Roskilde, Denmark). Cells were imaged 24 h after
transfection using a Zeiss LSM 510 Meta in confocal multitracking
mode, with a x100/1.4-oil Apochromat objective (Zeiss, Jena,
Germany) to generate 0.5 mm optical sections. Images were
analyzed using ImageJ (Rasband, W.S., ImageJ, U. S. National
Institutes of Health, Bethesda, Maryland, USA, http://imagej.nih.
gov/ij/1997-2011). The number of transfected cells showing
Venus or YFP complementation was quantified. As an index of the
complementation efficiency, the Venus or YFP fluorescence
intensity was measured in individual nuclei, and normalized to
the mCherry fluorescence intensity within the same cells. At least
100 cells were measured per condition. Linear brightness and
contrast adjustments were made for illustration purposes, but only
after the analysis had been made.
Immunofluorescence analysis was performed on cells grown and
transfected (when indicated) on coverslips, fixed for 10 min in 10%
formalin and permeabilized for 10 min in 0.5% Triton X-100 in
PBS. The primary antibodies were a rat anti-HA antibody
(Roche), a rabbit anti-c-Fos antibody (sc-52; Santa Cruz) and a
goat anti-TRAP220 (Med1) antibody (sc-5334; Santa Cruz).
Secondary antibodies were anti-rat, anti-rabbit and anti-goat
Alexa Fluor 488-conjugated antibodies (Invitrogen). When indi-
cated, nuclei were counterstained with DRAQ5 (Biostatus Ltd.,
Shepshed, UK). The transfected or immunofluorescently stained
array cells were imaged by confocal microscopy (see above). The
entire nucleus was scanned to generate 0.2 mm optical sections.
When detected, the array was typically present in 2 to 3
consecutive sections.
Peptide SPOT analysis
Peptide SPOT synthesis [43] was performed essentially as
described in [44]. Briefly, cellulose membrane-bound peptides
were prepared in an automated Spot synthesizer (MultiPep,
Intavis AG Bioanalytical Instruments, Köln, Germany) using
Fmoc derivatives of amino-acids (Novabiochem, Darmstadt,
Germany). GST-nTRIP6 was expressed in Escherichia coli
BL21 and purified using glutathione Sepharose 4B beads (GE
Healthcare, Freiburg, Germany). After activation of the mem-
branes with methanol the membrane-bound peptide arrays were
blocked for 3 h in blocking buffer (2% milk powder and 5%
sucrose in Tris-buffered saline (TBS), pH 8.0) and then incubated
overnight at 4uC with 10 mg/ml purified GST-nTRIP6 in
blocking buffer, which was then detected with an anti-GST
antibody (G1160; Sigma-Aldrich, München, Germany), revealed
by a horseradish peroxidase conjugated anti-mouse antibody
(Sigma-Aldrich) and ECL. The QRALAKDLIVPRRP peptide,
recognized by the anti-GST antibody, was used as a positive
control.
Reverse transcription and real-time PCR
Total RNA was extracted using PeqGOLD TriFast (Peqlab
Biotechnologie, Erlangen, Germany) and reverse-transcribed into
cDNA. The mRNAs for MMP1, MMP13 and the ribosomal
subunit 36B4 gene used for normalization, were quantified by real-
time PCR using the ABI Prism Sequence Detection System 7000
(Applied Biosystems, Foster City, CA). The primers (Invitrogen)
were as follows (59 to 39): MMP1: TGCTCATGCTTTTCAAC-





ChIP assays were performed using the ChIP-IT Express kit
(Active Motif, Rixensart, Belgium), following the manufacturer’s
instructions. Antibodies used were: anti-THRAP3 (Novus Biolog-
icals, Cambridge, United Kingdom), anti-c-Fos (sc52; Santa Cruz)
and anti-TRAP220 (Med1) (sc-5334; Santa Cruz). The isotype
control antibodies were purchased from Diagenode (Liège,
Belgium). Enrichment of the promoter of the MMP13 gene was
determined by real-time PCR using the primers GTCGCCACG-
TAAGCATGTT and CTGTTGTCTTTCCGCAGAGA, and
calculated as fold enrichment above background (isotype control
antibody) after normalization to the input (DDCt method).
Statistical analysis
Where indicated, significant differences were assessed by t-test
analysis, with values of P,0.05 sufficient to reject the null
hypothesis.
Results
nTRIP6 dimerizes through its N-terminal pre-LIM region
We have previously reported that nTRIP6 acts as a co-activator
for AP-1, NF-kB and GR [19–21]. However, nTRIP6 does not
harbour any functional domain known from other classical co-
activators. The only domains in nTRIP6 which could account for
a co-activator function are the three C-terminal LIM domains,
functioning as protein-protein interaction modules. The logical
hypothesis is therefore that the LIM domains are responsible for
the co-activator function. To directly address this hypothesis, we
made use of our prior observation that nTRIP6 co-activator
function is transferable [19], i.e. that a fusion of nTRIP6 to GAL4
DNA binding domain (GAL4DBD) activates the expression of a
reporter gene driven by GAL4-UAS (Fig. 1A). In this assay, the
LIM domains alone fused to GAL4DBD were sufficient to activate
the reporter gene. The level of activation was similar to that
achieved by a fusion of GAL4DBD with the full-length nTRIP6
(GAL4DBD-nTRIP6). Fusion of GAL4DBD with an nTRIP6
construct lacking the LIM domains (preLIM) had no effect on
reporter gene expression (Fig. 1A). These results suggest that, as
nTRIP6 Recruits the Mediator Complex
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expected, nTRIP6 exert its co-activator function via its LIM
domains. We thus studied whether the LIM domains are sufficient
to co-activate AP-1 in reporter gene assays. Overexpression of
nTRIP6 increased the responsiveness of the AP-1-dependent
MMP1 (collagenase I) promoter (MMP1-Luc) to the phorbol ester
TPA. However, overexpression of the LIM domains alone had no
effect on the expression of the reporter gene (Fig. 1B). This result
shows that the LIM domains lack a property needed for co-
activation on the more complex transcription factor-bound
promoter.
What could be the contribution of the pre-LIM region to the
AP-1 co-activation? To reconcile these apparently contradictory
results, we hypothesized that nTRIP6 homodimerizes through its
pre-LIM region, and that this dimerization is essential for the co-
activator function. We tested whether nTRIP6 interacts with itself
in living cells using bimolecular fluorescence complementation of
the Venus fluorescent protein (BiFC; [35]). Venus complementa-
tion was indeed observed in the nucleus of 80 to 90% of the cells
co-transfected with nTRIP6 fused to the N-terminus of Venus
(nTRIP6-VN) and nTRIP6 fused to the C-terminus of Venus
(nTRIP6-VC) (Fig. 2A). The LIM domains of nTRIP6 were
dispensable for this interaction, as indicated by the complemen-
tation between nTRIP6-VN and preLIM-VC (nTRIP6 N-
terminal pre-LIM region fused to VC; Fig. 2A). Furthermore, no
complementation was observed between nTRIP6-VN and the
LIM domains alone fused to VC (LIM-VC), although the cells
were efficiently transfected, as indicated by the cytosolic expression
of the red fluorescent protein mCherry fused to a nuclear export
sequence used as a transfection control (Fig. 2A). All VC and VN
fusion constructs were expressed and localized to the nucleus
(Fig. S1). Thus, nTRIP6 interacts with itself through its pre-LIM
region. Although we do not know about the stoichiometry of this
interaction, homodimerization or higher order complexes, we
refer to it as homodimerization for clarity.
If this dimerization were indeed required for the co-activator
function of nTRIP6, it should occur at the promoter of AP-1
dependent genes. To visualize the promoter-associated homo-
dimerization of nTRIP6, we generated a reporter cell line
containing an integrated array of multiple copies of the AP-1-
dependent MMP1-Luc reporter gene. The array was generated as
previously described [20,21], by transfecting the reporter plasmid
together with the pDBN-AR1 plasmid [39], which initiates events
similar to gene amplification in cancer cells, leading to tandem
repeats of up to 10 000 copies [39,45]. The high local
concentration of binding sites on the amplified gene array permits
the visualization of the binding of fluorescently tagged proteins, as
previously shown by us and others for NF-kB-, AP-1- and GR-
dependent array cell lines [20,21,42]. Using this method we
generated NIH-3T3 fibroblasts carrying several hundred integrat-
ed MMP1-Luc plasmid copies in discrete loci (Fig. S2). One of the
cell clones, clone 12c, was estimated by real-time PCR to have an
integrated array of about 2000 gene units. The presence of the
MMP1-Luc array was confirmed by DNA fluorescent in situ
hybridization using a fragment of the luciferase coding sequence as
a probe. The staining was restricted to a single spot within the
nucleus of the 12c cells, and was seen in 100% of the cells, whereas
only background staining was visible in the parental NIH-3T3 cells
(Fig. S2B). TPA treatment induced luciferase activity in clone 12c
(Fig. S2C), suggesting that AP-1 was able to bind to its cognate
response elements on the array and to activate transcription from
the MMP1-Luc genes. To confirm the functionality of the array,
we studied the recruitment of c-Fos, nTRIP6, the Mediator
complex protein Med1/TRAP220, and RNA polymerase II (Pol
II; Fig. S2D, E). Transfected nTRIP6 fused to YFP was located in
the nucleus, and was recruited to the array upon TPA treatment,
as shown by the enrichment to a single bright spot in the nucleus.
Similarly, Pol II fused to GFP, as well as endogenous c-Fos and
TRAP220/Med1, both detected by immunofluorescence, were
recruited to the array upon TPA treatment (Fig. S2D, E). This
specific enrichment to the array was observed in 70 to 80% of the
transfected cells. These results confirm that the MMP1-Luc array
is functional and responds to TPA treatment, and encouraged us
to test whether nTRIP6 homodimerizes on the promoter of an
AP-1 target gene, by performing BiFC assays in this array cell line.
Venus fluorescence complementation was observed in the nucleus
of the cells co-transfected with nTRIP6-VN and nTRIP6-VC.
The fluorescence complementation was enriched to the array
upon TPA treatment (Fig. 2B), suggesting that indeed nTRIP6
homodimers are recruited to the AP-1-bound promoter. To
confirm that the nTRIP6 homodimer is selectively recruited to the
promoter via an interaction with AP-1, we made use of a
previously established reporter cell line, which harbours an array
of a reporter gene driven by the minimal AP-1-dependent
enhancer of the urokinase type plasminogen activator (uPA) gene
(-1977/-1858uPA-TATA-Luc). The uPA gene enhancer [46,47]
harbours response elements for both the AP-1 complexes cJun:c-
Fos which interacts with nTRIP6, and for c-Jun:ATF2 which does
not interact with nTRIP6 [20]. To detect specific AP-1 complex-
dependent recruitment of the nTRIP6 homodimer, these array
cells were co-transfected with both nTRIP6 BiFC constructs,
together with ‘‘single chain’’ AP-1 constructs, in which the coding
sequences of either c-Jun and c-Fos, or c-Jun and ATF2 were fused
in frame using a flexible linker [37]. In the presence of the c-
Jun:ATF2 single chain AP-1, which does not interact with
nTRIP6, nTRIP6 homodimers were homogenously distributed
in the nucleus. However, in cells co-transfected with the c-Jun:c-
Fos construct, which does interact with nTRIP6, nTRIP6
homodimers were enriched to the array (Fig. 2C). Given that
Figure 1. The N-terminus of nTRIP6 is required for its co-
activator function. (A) HEK293 cells were cotransfected with a GAL-
Luc reporter construct and Ubi-Renilla, together with expression vectors
for either GALDBD or GALDBD fusions of nTRIP6, of nTRIP6 N-terminal pre-
LIM region (preLIM) or of only the 3 LIM domains (LIM). Normalized
luciferase activities are plotted relative to the activity obtained with
GALDBD (mean 6 SD of one representative experiment performed in
triplicates). (B) HEK293 cells were cotransfected with a luciferase
reporter gene driven by the AP-1-dependent MMP1 promoter (MMP1-
Luc) and Ubi-Renilla, together with either an empty vector (V), an
expression vector for nTRIP6 or for only the 3 LIM domains (LIM). Cells
were treated with TPA as indicated. Normalized luciferase activities are
plotted relative to untreated vector control (mean 6 SD of one
representative experiment performed in triplicates).
doi:10.1371/journal.pone.0097549.g001
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nTRIP6 is tethered to AP-1-bound promoters through a direct
interaction with c-Fos [20], these results strongly suggest that the
nTRIP6 homodimer is specifically recruited to the promoter via its
interaction with AP-1.
Our results show that the pre-LIM region of nTRIP6 mediates
homodimerization. To further map the dimerization site, we
performed a peptide SPOT analysis [43]. Overlapping peptides
covering the pre-LIM region of nTRIP6 were synthesized on
nitrocellulose membranes, which were then probed with recom-
binant nTRIP6 fused to GST (Fig. 2D). This screen identified 2
peptides able to interact with nTRIP6, AQPVRGCGPPRRG and
EDELDRLTKKLVH, corresponding to amino acid positions
175-187 and 253-265, respectively. We then tested the involve-
ment of these 2 domains, named Dimerization Domain (DD)1 and
DD2 respectively, in the homodimerization of nTRIP6 using the
BiFC assay (Fig. 2E). The complementation between the VC and
VN fusions of nTRIP6 lacking DD1, as well as the complemen-
tation of the constructs lacking DD2, was strongly reduced
compared to the complementation observed with the wild type
constructs. The wild type and deletion constructs fused to VC and
VN were expressed at similar levels and located in the nucleus
(Fig. S3). This result indicates that both domains are required for
the optimal homodimerization of nTRIP6.
nTRIP6 homodimerization is required for its co-activator
function
In order to now address the functional relevance of nTRIP6
homodimerization, we designed short peptides corresponding to
the 13 amino acid sequences of the dimerization domains, with the
prediction that they should competitively block dimerization. The
peptides were fused to a nuclear localization signal (NLS) to
prevent any interference with a putative dimerization of TRIP6 in
Figure 2. nTRIP6 dimerizes through discrete domains of its pre-LIM region. (A) HeLa cells were cotransfected with an expression vector for
nTRIP6 fused to the N-terminal part of the Venus fluorescent protein (VN), and with an expression vector for either nTRIP6, nTRIP6 N-terminal pre-LIM
region (preLIM) or only the 3 LIM domains (LIM) fused to the C-terminal part of Venus (VC), together with mCherry fused to a nuclear export signal
(NES) as a transfection control. Cells were counterstained with DRAQ5 and imaged by confocal microscopy. The Venus fluorescence
complementation (Compl.) was observed in 80 to 90% of the cells transfected with nTRIP6-VN and nTRIP6-VC or preLIM-VC, but in none of the
cells transfected with nTRIP6-VN and LIM-VC. (B, C) nTRIP6 dimerizes at the promoter of AP-1 target genes. NIH-3T3 fibroblast cell lines containing an
integrated array of multiple copies of the indicated reporter gene were cotransfected with nTRIP6-VN and nTRIP6-VC. Cells were treated for 3 h with
TPA (B) or cotransfected with an expression vector for either the single chain AP-1 c-Jun,ATF2 or the single chain AP-1 c-Jun,c-Fos (C). Cells were
imaged by confocal microscopy. Nuclei of representative cells are shown. A selective enrichment of the Venus complementation to the array (arrow)
was observed in 70 to 80% of the TPA-treated cells (B) and the c-Jun,c-Fos-transfected cells showing complementation (C). (D) Mapping of two
nTRIP6 dimerization domains. Peptides spanning the entire sequence of nTRIP6 pre-LIM region were synthesized on a cellulose membrane as 15
mers, each shifted by 3 amino-acids. The membrane was incubated with recombinant nTRIP6 fused to GST, which was then detected by an anti-GST
antibody. The two positive spots boxed in green correspond to a control peptide recognized by the anti-GST antibody. (E) Both domains are required
for nTRIP6 dimerization. HeLa cells were cotransfected with the indicated combination of expression vectors for nTRIP6, nTRIP6 lacking the
dimerization domain 1 (DDD1) or nTRIP6 lacking the dimerization domain 2 (DDD2), fused to either VN or VC, together with the mCherry-NES
expression vector as a transfection control. Venus complementation was quantified by measuring the Venus fluorescence intensity in individual
nuclei, normalized to the mCherry fluorescence intensity within the same cells, and is presented as arbitrary units (a.u.; mean 6 SD of three
independent experiments). Representative images are shown in Fig. S3C.
doi:10.1371/journal.pone.0097549.g002
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the cytosol, and to mCherry to trace their expression and
localization. Both DD1 and DD2 peptides inhibited nTRIP6
homodimerization in the BiFC assay, whereas scrambled versions
of the peptides used as controls, had no effect (Fig. 3A).
Quantification of the complementation showed that the DD1
peptide was more efficient than the DD2 peptide (Fig. 3B).
Furthermore, sequence alignment of the corresponding pre-LIM
regions of related LIM domain proteins of the zyxin family showed
high conservation of the DD2 sequence, but not of the DD1
sequence (Fig. S4). Thus, the DD2 peptide might also affect the
function of other LIM domain proteins. For these reasons, only the
DD1 peptide was used for further experiments. We first used it to
study whether nTRIP6 homodimerization is required for its co-
activator function in reporter gene assays (Fig. 4A). The peptide
dose-dependently reduced the induction by TPA of the MMP1-
Luc reporter gene, whereas the scrambled control peptide had no
effect (Fig. 4A). Importantly, the DD1 peptide did not interfere
with the interaction between AP-1 and nTRIP6 (Fig. S5). As an
additional specificity control, the DD1 and the scrambled control
peptides were fused to a nuclear export signal (NES) instead of an
NLS. The NES-DD1 peptide had no effect on the induction of the
MMP1-Luc reporter gene (Fig. S6). We then studied the effect of
the peptide on the induction of endogenous AP-1-regulated genes.
In HEK293 cells, overexpression of the DD1 peptide repressed the
induction by TPA of the AP-1 target genes MMP-1 and MMP13,
whereas the control scrambled peptide had no effect (Fig. 4B, C).
nTRIP6 homodimers mediate the promoter recruitment
of THRAP3 and of the Mediator complex
Together, our results show that nTRIP6 dimerizes via discrete
domains within its pre-LIM region, in order to exert its co-
activator function through its LIM domains. Given that LIM
domains are not co-activator domains per se but protein-protein
interaction modules, the logical hypothesis is that nTRIP6
homodimers mediate the recruitment of other co-activator or co-
activator complexes to the transcription factor-bound promoter. In
a proteomics-based large-scale study of protein-protein interac-
tions [48], we identified TRIP6 as interacting with the thyroid
hormone receptor–associated protein 3 (THRAP3 or TRAP150),
a subunit of the Mediator complex [49]. We therefore tested
whether nTRIP6 interacts with THRAP3 in the nucleus of HeLa
cells using the BiFC assay (Fig. 5A, B). YFP fluorescence
complementation indeed documented this interaction. It was
observed in the nucleus of 80 to 90% of the cells co-transfected
with nTRIP6 fused to the C-terminal half of YFP (YC) together
with THRAP3 fused to the N-terminal half of YFP (YN).
Furthermore, a similar complementation was observed in cells
co-transfected with the LIM domains alone fused to YC and
THRAP3-YN, showing that the N-terminal pre-LIM region is
dispensable for this interaction. To study the contribution of the
individual LIM domains of nTRIP6 to its interaction with
THRAP3, we mutated in the BiFC construct the coordinating
cysteines of the two zinc fingers of each LIM domain to alanines.
Figure 3. Blocking peptides inhibit nTRIP6 dimerization. HeLa cells were cotransfected with expression vectors for nTRIP6 fused to the N-
terminal part of Venus and for nTRIP6 fused to the C-terminal part of Venus, together with expression vectors for either mCherry fused to a nuclear
localization signal (NLS), a peptide corresponding to the sequence of the dimerization domain 1 fused to an NLS and to mCherry (DD1), a scrambled
version of the DD1 peptide (DD1c), a peptide corresponding to the sequence of the dimerization domain 2 fused to an NLS and to mCherry (DD2), or
a scrambled version of the DD2 peptide (DD2c). (A) Venus complementation (Compl.) was imaged by confocal microscopy and representative cells
are shown. (B) Complementation was quantified by measuring the Venus fluorescence intensity in individual nuclei, normalized to the mCherry
fluorescence intensity within the same cells, and is presented as arbitrary units (a.u.; mean 6 SD of three independent experiments).
doi:10.1371/journal.pone.0097549.g003
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Cells co-transfected with THRAP3-YN together with either of the
three nTRIP6 LIM mutants fused to YC showed significantly
reduced complementation as compared to the wild type nTRIP6
construct (Fig. 5A, B), suggesting that all three LIM domains
participate in the interaction.
Is the nTRIP6-THRAP3 interaction relevant for the activation
of AP-1 dependent transcription? To tackle this question, we first
tested whether THRAP3 acts on AP-1-regulated promoters. In
Cos7 cells, overexpression of THRAP3 dose-dependently in-
creased the induction of the AP-1-dependent reporter gene by
TPA (Fig. 5C). Conversely, silencing THRAP3 by siRNA
inhibited the induction of the reporter gene (Fig. 5E) and of the
endogenous AP-1 target genes MMP1 and MMP13 by TPA
(Fig. 5F, G), while it had no effect on the induction of c-Fos by
TPA (Fig. 5D). We then used the MMP1-Luc array cells to study
the promoter recruitment of THRAP3. A transfected YFP fusion
of THRAP3 was located in the nucleus, and was recruited to the
array upon TPA treatment, as shown by the enrichment to a single
bright spot in the nucleus (Fig. 5H). These results were confirmed
by chromatin immunoprecipitation (ChIP) experiments, which
showed that endogenous THRAP3 was recruited to the MMP13
promoter upon induction (Fig. 5I). Thus, THRAP3 is a co-
activator for AP-1. Given the interaction of THRAP3 with
nTRIP6, the co-activator function of THRAP3 should depend on
nTRIP6 homodimerization. We again used the array cells to test
this hypothesis. Co-transfection of the DD1 peptide, which blocks
nTRIP6 dimerization, significantly reduced the recruitment of
THRAP3-YFP to the array, as compared to the scrambled control
peptide (Fig. 6A, C). This result strongly suggests that the
promoter recruitment of THRAP3 depends on nTRIP6 homo-
dimerization. Since THRAP3 is a subunit of the Mediator
complex, the promoter recruitment of other Mediator complex
components might also require nTRIP6 homodimerization.
Indeed, the TPA-induced recruitment of a core Mediator complex
subunit, Med1/TRAP220, was inhibited by the DD1 peptide, as
assessed by immunofluorescence analysis of the array cells (Fig. 6B,
C). Together, these results show that THRAP3 is an nTRIP6
homodimer-dependent AP-1 co-activator, and strongly suggest
that nTRIP6 mediates the recruitment of the Mediator complex to
AP-1-bound promoters via an interaction with THRAP3.
GR inhibits the recruitment of THRAP3 to AP-1-regulated
promoters
We have previously reported that nTRIP6 is also involved in the
transrepression of AP-1 by GR [19,20]. In this mode of repression
by GR, the interaction between nTrip6 and c-Fos in not disrupted,
and nTrip6 recruitment to the c-Fos bound promoter is not
prevented. Rather, one important function of nTrip6 in
transrepression is to mediate the tethering of GR to the
promoter-bound AP-1 [19,20]. Given that nTRIP6 dimerization
is essential for its co-activator function, we tested whether GR
inhibits nTRIP6 dimerization. In the BiFC assay, the comple-
mentation between nTRIP6-VN and nTRIP6-VC was not
affected by the dexamethasone-mediated activation of co-trans-
fected mCherry-GR (Fig. S7). Thus, GR does not hamper
nTRIP6 dimerization. The next logical hypothesis is that the
tethering of GR interferes with the recruitment of nTRIP6-
dependent co-activators. The LIM domains of nTRIP6 are
required for the interaction with both THRAP3 and GR. Thus,
we speculated that THRAP3 and GR might compete for the
interaction with nTRIP6. In a BiFC assay, the complementation
between nTRIP6-YC and THRAP3-YN was significantly reduced
by overexpressed GR (Fig. 7A, B), showing that GR inhibits the
interaction between nTRIP6 and THRAP3. We then studied by
ChIP the effect of GR on THRAP3 recruitment to an AP-1-
regulated promoter (Fig. 7C). As previously reported [29],
dexamethasone treatment did not interfere with the recruitment
of c-Fos to the MMP13 promoter. However, the TPA-induced
recruitment of THRAP3 was strongly inhibited by dexamethasone.
Figure 4. The DD1 peptide inhibits AP-1. (A) HEK293 cells were
cotransfected with the AP-1-dependent MMP1-Luc reporter construct
and Ubi-Renilla, together with either a control empty vector (V) or
increasing amounts of an expression vector for the mCherry-NLS fusion
of the DD1 peptide or its scrambled version (DD1c). Cells were treated
with TPA as indicated. Normalized luciferase activities are plotted
relative to untreated vector control (mean 6 SD of one representative
experiment performed in triplicates). (B, C) HEK293 cells were
transfected with either a control empty vector, an expression vector
for the mCherry-NLS fusion of the DD1 peptide or its scrambled version
(DD1c). Cells were treated with TPA as indicated. The relative levels of
MMP1 (B) and MMP13 (C) mRNAs were determined by reverse
transcription and real-time PCR, and are plotted relative to the
untreated vector control (mean 6 S.D. of three independent
experiments).
doi:10.1371/journal.pone.0097549.g004
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Figure 5. THRAP3 is a co-activator for AP-1. (A) THRAP3 interacts with nTRIP6. HEK293 cells were cotransfected with THRAP3 fused to the N-
terminal part of YFP (YN) together with C-terminal part of YFP (YC) fusions of either nTRIP6, only the 3 LIM domains (LIM), or nTRIP6 mutants in which
two of the coordinating cysteines in the two zinc fingers of the LIM domain 1 (LIM1m), of the LIM domain 2 (LIM2m) or of the LIM domain 3 (LIM3m)
were mutated to alanines. The cells were cotransfected with mCherry fused to a nuclear export signal (NES) as a transfection control. Cells were
imaged by confocal microscopy and representative images are shown. (B) The relative YFP complementation (Compl.) was quantified by measuring
the YFP fluorescence intensity in individual nuclei, normalized to the mCherry fluorescence intensity within the same cells, and is presented in
arbitrary units (a.u.; mean 6 SD of three independent experiments; *, P,0.05). (C) Cos7 cells were cotransfected with the AP-1-dependent MMP1-Luc
reporter construct, together with either a control empty vector (V) or increasing amounts of an expression vector for THRAP3. Cells were treated with
TPA as indicated. Luciferase activities are plotted relative to untreated vector control (mean 6 SD of one representative experiment performed in
triplicates). (D–G) HEK293 cells were transfected with either a control siRNA (Con) or an siRNA targeting THRAP3, together with the MMP1-Luc
reporter construct and Ubi-Renilla (E). Cells were treated with TPA as indicated. (D) Cell lysates were subjected to Western Blotting using antibodies
against THRAP3, c-Fos and actin as a loading control. (E) Normalized luciferase activities are plotted relative to the values obtained with untreated
control siRNA transfected cells (mean 6 SD of one representative experiment performed in triplicates; *, P,0.05). (F, G) The relative levels of MMP1
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Similarly, dexamethasone treatment inhibited the TPA-induced
recruitment of Med1/TRAP220 (Fig. 7C). Thus, GR represses the
recruitment of THRAP3, an nTRIP6-dependent AP-1 co-activator.
Discussion
We report here that (i) the transcriptional co-activator function
of nTRIP6, the nuclear isoform of the LIM domain protein
TRIP6, requires its homodimerization, (ii) nTRIP6 homodimers
mediate the promoter recruitment of the Mediator complex
(F) and MMP13 (G) mRNAs were determined by reverse transcription and real-time PCR, and are plotted relative to the values obtained with
untreated control siRNA transfected cells (mean 6 S.D. of three independent experiments; *, P,0.05). (H) NIH-3T3 fibroblast cells containing an
integrated array of multiple copies of the MMP1-Luc reporter gene were transfected with a YFP fusion of THRAP3, treated for 3 h with solvent alone
(Con) or TPA and imaged by confocal microscopy. Nuclei of representative cells are shown. A selective enrichment of the YFP fluorescence to the
array (arrow) was observed in 60 to 70% of the transfected, TPA-treated cells. (I) Chromatin immunoprecipitation (ChIP) was performed in HEK293
cells treated with TPA as indicated, using the indicated antibodies (Ab) or isotype control antibodies. Enrichments of the MMP13 gene promoter were
determined by real-time PCR, and plotted as fold enrichment above background (isotype control antibody) after normalization to the input (mean 6
SD of three independent experiments).
doi:10.1371/journal.pone.0097549.g005
Figure 6. nTRIP6 homodimerization is required for the promoter recruitment of THRAP3 and of the Mediator complex. The MMP1-
Luc array cells were co-transfected with THRAP3 fused to YFP (A) or an empty vector (B), together with either the mCherry-NLS fusion of the DD1
peptide or its scrambled version (DD1c). Cells were treated with solvent alone (Con.) or TPA for 3 h as indicated. Empty vector transfected cells were
subjected to immunofluorescent labelling using an anti-Med1/TRAP220 antibody (B). Cells were imaged by confocal microscopy, and nuclei of
representative cells are shown. The arrow depicts the enrichment of the fluorescence to the array. (C) The number of cells in which the array was
visible was counted, and is presented as percent of the transfected cells (mean 6 SD of three independent experiments; *, P,0.05).
doi:10.1371/journal.pone.0097549.g006
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component THRAP3, which thereby acts as a co-activator for AP-
1, and (iii) GR represses AP-1 activity at least in part by preventing
the nTRIP6-mediated recruitment of THRAP3.
nTRIP6 acts as a homodimer
We had previously shown that nTRIP6 acts as a co-activator for
several transcription factors, although it does not harbour any
known co-activator domain. Given that nTRIP6 carries three
protein interaction domains (LIM domains), it is plausible that it
acts as an adaptor co-activator. The LIM domain would serve not
only to interact with the promoter-bound transcription factor [19–
21], but also for the assembly of other regulatory proteins.
Surprisingly, our results show that not only the LIM domains, but
also the N-terminal pre-LIM region of nTRIP6 participate in the
co-activator function. An earlier analysis of TRIP6 transcriptional
regulatory function had suggested that TRIP6 contains at least two
‘‘transactivation domains’’, one located within the LIM domain
region and the other within the pre-LIM region [50]. According to
our results both regions exert essential yet different functions:
discrete domains within the pre-LIM mediate nTRIP6 homo-
dimerization, whereas the LIM domains are directly involved in
transcriptional activation via the recruitment of co-activators, in
particular the novel AP-1 co-activator THRAP3. The LIM
domains alone covalently fused to a DNA binding domain
(GAL4DBD) can activate transcription, showing that they are
sufficient to interact with and recruit co-activators. Indeed,
THRAP3 interacts with the LIM domains of nTRIP6 and its
promoter recruitment depends on nTRIP6. Thus, nTRIP6
regulates transcription as an adaptor co-activator, similarly to
LIM-only proteins. However, when nTRIP6 was recruited to the
promoter via the interaction of its LIM domains with a promoter-
bound transcription factor, the LIM domains were not sufficient to
co-activate AP-1. The N-terminal pre-LIM region was essential for
the co-activator function, by mediating the homodimerization of
nTRIP6. Although, from the BiFC experiments, nTRIP6 interacts
with itself, we cannot conclude as to the stoichiometry of the
complex: nTRIP6 exists at least as a homodimer, but we cannot
exclude the existence of higher order complexes. We identified two
dimerization domains within the pre-LIM region of nTRIP6, one
of which is conserved in other related LIM domain proteins of the
Zyxin family. Thus, it is tempting to speculate that these other
LIM domain proteins also dimerize, which might be important for
their reported transcriptional co-regulator action [51–56]. Why is
nTRIP6 homodimerization required for its co-activator function?
nTRIP6 uses its LIM domains for interacting with both the
transcription factors and the co-activator THRAP3. Thus, if
nTRIP6 were recruited as a monomer to the promoter-bound
transcription factor, then the LIM domains might not be accessible
Figure 7. GR prevents the recruitment of THRAP3. (A, B) HEK293 cells were cotransfected with nTRIP6 fused to the C-terminal part of YFP (YC)
and THRAP3 fused to the N-terminal part of YFP (YN), together with either a control empty vector (V) or increasing amounts of an expression vector
for GR, and mCherry fused to a nuclear export signal (NES) as a transfection control. Cells were imaged by confocal microscopy. (A) Images of
representative cells are shown. (B) YFP complementation was quantified by measuring the YFP fluorescence intensity in individual nuclei, normalized
to the mCherry fluorescence intensity within the same cells, and is presented in arbitrary units (a.u.; mean 6 SD of three independent experiments;
*, P,0.05). (C) HEK293 cells were treated TPA in the presence or absence of dexamethasone (Dex) as indicated, and chromatin immunoprecipitation
was performed on the MMP13 promoter using the indicated antibodies (Ab) or isotype control antibodies. Enrichments of the MMP13 gene promoter
were determined by real-time PCR, and plotted as fold enrichment above background (isotype control antibody) after normalization to the input
(mean 6 SD of three independent experiments; *, P,0.05).
doi:10.1371/journal.pone.0097549.g007
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for an interaction with THRAP3, which appears to depend on all
three LIM domains. In an nTRIP6 homodimer, one set of LIM
domains would mediate the recruitment to the promoter-bound
transcription factor, and the second set would be available to
interact with and recruit other co-activators such as THRAP3.
This scenario is corroborated by our observation that blocking
nTRIP6 dimerization abolishes the promoter recruitment of
THRAP3.
THRAP3 is an nTRIP6-dependent AP-1 co-activator
Based on its ability to interact with nTRIP6, we have identified
THRAP3 as a novel co-activator for AP-1: (i) overexpression of
THRAP3 increased the transcriptional activity of AP-1, while (ii)
silencing of THRAP3 reduced the expression of AP-1 target genes,
and (iii) THRAP3 was indirectly recruited to the AP-1-bound
promoter in an nTRIP6 homodimer dependent manner.
THRAP3 was first identified as a component of the Mediator
co-activator complex [49], and has since been shown to co-activate
several transcription factors, such as the Peroxisome proliferator-
activated receptor gamma [57] and the heterodimeric transcrip-
tion factor circadian locomotor output cycles kaput (CLOCK)-
brain, muscle Arnt-like 1 (BMAL1) [58]. The siRNA targeting
THRAP3 did not totally abolish the induction of AP-1 target
genes (Fig. 5F, G). However, the knockdown of THRAP3 was not
total (Fig. 5D). A likely interpretation is that the expression of
THRAP3 is not limiting for its co-activator function, and that the
residual THRAP3 levels after silencing are sufficient to promote
transcription. The fact that THRAP3 is expressed at relatively
high levels is not entirely surprising considering the other functions
of THRAP3, for example in splicing or in the DNA damage
response [38,59]. This might also explain why THRAP3
overexpression only moderately increased AP-1 activity (Fig. 5B).
THRAP3 most likely does not represent a core component of
the Mediator complex [60–62]. Indeed, several types of function-
ally distinct Mediator complexes, which vary in their composition,
have been described (reviewed in [63,64]). The Mediator complex
proteins MED1 and MED14 have been identified as interacting
with the GR [65]. How the Mediator complex is recruited to AP-1
has remained elusive. Our results reveal that inhibiting the
recruitment of THRAP3 by blocking nTRIP6 dimerization also
inhibited the recruitment of another Mediator complex subunit
(Med1/TRAP220). This is, to our knowledge, the first identifica-
tion of the mechanism whereby the Mediator complex is recruited
to AP-1-regulated promoters. Furthermore, this observation
suggests that a THRAP3-containing Mediator complex subtype
is indirectly recruited to AP-1 target genes through the interaction
between THRAP3 and nTRIP6. Thus, the function of THRAP3
in AP-1 co-activation may be to recruit the Mediator complex, as
is the case for THRAP3-mediated CLOCK/BMAL1 co-activa-
tion [58]. Whether the association of THRAP3 with the Mediator
complex is regulated is not known. It was recently reported that
THRAP3 can be phosphorylated on several serine residues [59].
Thus, it might be possible that the AP-1 activation pathway also
leads to a phosphorylation-dependent association of THRAP3
with the Mediator complex, and a subsequent recruitment of the
complex to AP-1-bound promoters. However, we cannot exclude
the possibility that THRAP3 and the Mediator complex are both
independently recruited to the promoter in an nTrip6-dependent
manner. In such a scenario, THRAP3 would co-activate AP-1
independently from the action of the Mediator complex, possibly
via the regulation of histone tail modification, since THRAP3
interacts with the lysine demethylase Jumonji [66].
Mechanism of GR-mediated repression of AP-1 activity
Several mechanisms have been reported for the so-called
crosstalk between GR and other transcription factors (reviewed
in [67–69]). We have previously reported that nTRIP6 is essential
in the negative crosstalk between GR and AP-1, in that it serves as
an adaptor for the tethering of GR to the promoter-bound AP-1,
which leads to transcriptional repression [19,20]. We have now
revealed a mechanism whereby the nTRIP6-dependent recruit-
ment of GR leads to the inhibition of AP-1 activity. Given that
nTRIP6 dimerization is essential for its co-activator function, one
could have assumed that GR represses AP-1 by preventing the
dimerization of nTRIP6. After ruling out this hypothesis, we
showed that a competition between GR and THRAP3 for their
interaction with nTRIP6 forms the basis of repression. While the
second and third LIM domains of nTRIP6 are engaged in the
interaction with the GR [19,21], all three LIM domains
participate in the interaction with THRAP3, indeed raising the
possibility of a competition. Although there is a selectivity in the
interaction between LIM domains and their binding partners,
competitive binding has already been reported, for example in the
case of LIM-only proteins (reviewed in [70]). Our results showing
a decreased interaction between THRAP3 and nTRIP6 in the
presence of GR confirmed that GR and THRAP3 compete for
interaction with nTRIP6. Moreover, GR prevented the recruit-
ment of THRAP3 to the activated MMP13 promoter, confirming
Figure 8. Model of nTRIP6-mediated regulation of AP1. nTRIP6
homodimerizes via 2 domains (depicted in red) within its N-terminal
pre-LIM region. In activating conditions (A), nTRIP6 homodimers are
recruited to the AP-1-bound promoter via an interaction of one set of
LIM domains, and mediate the recruitment of THRAP3 and of the
Mediator complex, via the other set of LIM domains. In repressing
conditions (B), the glucocorticoid receptor (GR) is tethered to the
promoter through an interaction with the LIM domains of nTRIP6,
which prevents the recruitment of THRAP3 and of the Mediator
complex.
doi:10.1371/journal.pone.0097549.g008
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that this competition occurs at the promoter of target genes. Given
that THRAP3 is essential for the transcriptional activity of AP-1,
the competition between THRAP3 and GR, resulting in an
inhibition of THRAP3 promoter recruitment upon GR activation,
most likely contributes to the GR-mediated repression of AP-1
activity. Finally, the observation that GR also inhibited the
recruitment of Med1/TRAP220 further supports the idea that
THRAP3 is the subunit responsible for the recruitment of the
Mediator complex to AP-1-activated promoters. Thus, we propose
that GR transrepresses AP-1 at least in part by displacing a
THRAP3-containing Mediator complex from the promoter-
bound nTRIP6-AP-1 complex.
In conclusion, we propose a model (Fig. 8) whereby nTRIP6
orchestrates the assembly of transcriptional co-regulators at AP-1-
regulated promoters. Two domains in the N-terminal pre-LIM
region of nTRIP6 mediate homodimerization, which enables one
set of LIM domains to interact with promoter-bound AP-1, and
the other set to recruit other co-activators such as THRAP3 and
the Mediator complex. In the presence of glucocorticoids, the LIM
domains-mediated tethering of GR prevents the recruitment of
THRAP3 and the Mediator complex. Therefore, through the
binding specificities of its multiple protein-protein interaction
domains, nTRIP6 functions as a dual adaptor co-regulator,
integrating both activating and repressing signals at the same
transcription factor-bound promoter.
Supporting Information
Figure S1 Expression of the BiFC constructs. HeLa cells
were transfected with expression vectors for nTRIP6 fused to the
N-terminal part of Venus (VN), for nTRIP6, nTRIP6 pre-LIM
region lacking the 3 LIM domains (preLIM) or for only the 3 LIM
domains (LIM) fused to the C-terminal part of Venus (VC). Cells
were subjected to immunofluorescent labelling using an anti-HA
antibody and counterstained with DRAQ5. Cells were imaged by
confocal microscopy.
(TIF)
Figure S2 Characterization of the AP-1-dependent re-
porter gene array cell line. (A) Schematic representation of
the AP-1-regulated gene unit amplified in the clone 12c. (B) Clone
12c and parental NIH-3T3 fibroblasts were subjected to DNA in
situ hybridization using a fluorescently labelled cDNA probe
complementary to the luciferase coding sequence (see Material
and Methods S1). A single gene array is visible in the nucleus
(delimited by dotted lines) of 100% of the 12c cells. (C) Clone 12c
cells and parental NIH-3T3 fibroblasts were treated with solvent
alone (con) or TPA as indicated. Luciferase activities are presented
relatively to the untreated parental NIH-3T3 cells (mean 6 S.D.
of one representative experiment performed in triplicates). (D)
nTRIP6 and RNA polymerase II are recruited to the gene array.
12c cells were transfected with GFP tagged RNA polymerase II
(GFP-Pol2) or nTRIP6 fused to YFP. Cells were treated with
solvent (con) or TPA for 3 h and imaged by confocal microscopy.
(E) 12c cells were treated with solvent or TPA for 3 h, and
endogenous c-Fos and Med1/TRAP220 were detected by
immunofluorescence and confocal microscopy. Nuclei of repre-
sentative cells are shown. The enrichment of RNA polymerase II,
nTrip6, CBP and Med1/TRAP220 to the gene array upon TPA
treatment (arrow) was observed in 70–80% of the transfected cells.
(TIF)
Figure S3 Expression and localization of the BiFC
fusions of nTRIP6 mutants lacking one dimerization
domain. HeLa cells were transfected with HA-tagged expression
vectors for nTRIP6 or nTRIP6 lacking either the dimerization
domain 1 (HA-nTRIP6DDD1) or the dimerization domain 2 (HA-
nTRIP6DDD2), fused to either the N-terminal half (VN) or the C-
terminal half (VC) of Venus. (A) Cell lysates were subjected to
Western Blotting using an anti-HA antibody or an anti-GR
antibody as a loading control. (B) Cells were subjected to
immunofluorescent labelling using an anti-HA antibody, counter-
stained with DRAQ5, and imaged by confocal microscopy. (C)
Representative images of the results in Fig. 2E. HeLa cells were
cotransfected with the indicated combination of expression vectors
for nTRIP6, nTRIP6DDD1 or nTRIP6DDD2, fused to either VN
or VC, together with the mCherry-NES expression vector as a
transfection control. Cells were imaged by confocal microscopy
and representative cells are shown.
(TIF)
Figure S4 Alignment of the N-terminal pre-LIM regions
of proteins from the Zyxin family. The residues correspond-
ing to the dimerization domains (DD) 1 and 2 are boxed. The
multiple sequence alignment was performed using the MultAlin
software [71].
(TIF)
Figure S5 The blocking peptide does not prevent the
interaction between nTRIP6 and AP1. HeLa cells were co-
transfected with expression vectors for nTRIP6 fused to the N-
terminal part of YFP (YN), and for the single chain AP-1 c-Jun,c-
Fos fused to the C-terminal part of YFP (YC), together with
expression vectors for either mCherry fused to a nuclear
localization signal (NLS; V), a peptide corresponding to the
sequence of the dimerization domain 1 fused to an NLS and to
mCherry (DD1), or a scrambled version of the DD1 peptide
(DD1c). Cells were imaged by confocal microscopy. Representa-
tive images are shown in (A). In (B), YFP complementation was
quantified by counting the number of transfected cells (mCherry
positive) showing complementation (mean 6 SD of three
independent experiments).
(TIF)
Figure S6 The DD1 peptide does not inhibit AP-1 when
targeted to the cytosol. (A) HEK293 cells were co-transfected
with a luciferase reporter gene driven by the AP-1-dependent
MMP1 promoter (MMP1-Luc) and Ubi-Renilla, together with
either an expression vector for mOrange fused to a nuclear export
signal (NES) as a control (V), or increasing amounts of an
expression vector for the mOrange-NES fusion of the DD1
peptide (NES-DD1). Cells were treated with TPA as indicated.
Normalized luciferase activities are plotted relative to the
untreated vector control (mean 6 SD of one representative
experiment performed in triplicates). (B) HEK293 cells were
transfected with the indicated constructs and imaged by confocal
microscopy. Representative cells are shown.
(TIF)
Figure S7 GR does not prevent nTRIP6 dimerization.
HeLa cells were co-transfected with nTRIP6 fused to the N-
terminal part of Venus (VN) and nTRIP6 fused to the C-terminal
part of Venus (VC), together with GR fused to mCherry. Cells
were treated with dexamethasone (Dex) or solvent as a control
(Con), and imaged 1 h later by confocal microscopy. Images of
representative cells are shown.
(TIF)
Material and Methods S1
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